FIRVANQ KIT (vancomycin hydrochloride) · AZURITY
Vancomycin hydrochloride is indicated for the treatment of Clostridium difficil e‑associated diarrhea in adults and pediatric patients less than 18 years of age. Important Limitations of Use Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2018-01-26
- Patent Cliff
- 2035
- Routes
- ORAL
- Dosage Forms
- FOR SOLUTION
FIRVANQ KIT Approval History
What FIRVANQ KIT Treats
5 indicationsFIRVANQ KIT is approved for 5 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Staphylococcal Endocarditis
- Septicemia
- Bone Infection
- Lower Respiratory Tract Infection
- Skin Infection
FIRVANQ KIT Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to FIRVANQ KIT
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
4 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05766670 | W81XWH-22-10937 W81XWH-22-10937 | Ph 3 | recruiting | Intramedullary Calcium Sulfate Antibiotic Depot |
| NCT04500275 | A-BR-109-013 | Ph 4 | completed | Topical Vancomycin Over Sternal Edge in Cardiac Surgery |
| NCT06126614 PREVENT-iT | PiT-2023 | Ph 3 | recruiting | Infection Prophylaxis in Total Joint Replacement |
| NCT07913347 ROOT | MGT-006-UC-G1201 jRCT2071260030 | Ph 1, Ph 2 | recruiting | Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study) |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
FIRVANQ KIT FDA Label Details
Indications & Usage
FDA Label (PDF)Vancomycin hydrochloride is indicated for the treatment of Clostridium difficil e‑associated diarrhea in adults and pediatric patients less than 18 years of age. Vancomycin hydrochloride is also indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin‑resistant strains) in adults and pediatric patients less than 18 years of age. Important Limitations of Use Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. Orally administered vancomycin hydrochloride is n...
FIRVANQ KIT Patents & Exclusivity
Patents (7 active)
Pro Intelligence Preview
Deep insights for FIRVANQ KIT
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2035
- • 40 active patents
Trial Analysis
- • 118 total trials
- • Stage: Declining
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment